APA (7th ed.) Citation

Suzuki, K., Fujimori, Y., Sakai, C., Tsuchiya, H., & Koroki, Y. (2025). Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan. Cancers, 17(9), 1389. https://doi.org/10.3390/cancers17091389

Chicago Style (17th ed.) Citation

Suzuki, Kazuhito, Yuma Fujimori, Chika Sakai, Hiroaki Tsuchiya, and Yosuke Koroki. "Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan." Cancers 17, no. 9 (2025): 1389. https://doi.org/10.3390/cancers17091389.

MLA (9th ed.) Citation

Suzuki, Kazuhito, et al. "Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan." Cancers, vol. 17, no. 9, 2025, p. 1389, https://doi.org/10.3390/cancers17091389.